Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002111 · ClinicalTrials.gov registry record · Phase 1
A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00002111: Completed Phase 1 study, sponsored by Stanford University.
NCT00002111 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002111, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
To investigate the toxicity, antiviral activity, and pharmacokinetics in HIV-infected patients receiving 16 weeks of oral saquinavir mesylate ( Ro 31-8959 ) at one of two doses.
Interventions
- DRUG Saquinavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002111
The ClinicalTrials.gov registry entry for NCT00002111 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Saquinavir is the first listed.
NCT00002111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002111 about?
NCT00002111 is a clinical study titled "A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.". To investigate the toxicity, antiviral activity, and pharmacokinetics in HIV-infected patients receiving 16 weeks of oral saquinavir mesylate ( Ro 31-8959 ) at one of two doses.
What is the current status of trial NCT00002111?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants.
What interventions are being tested in trial NCT00002111?
The interventions under investigation include: Saquinavir (DRUG).
Who is sponsoring clinical trial NCT00002111?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.